Published in final edited form as:

Oral Oncol. 2012 December ; 48(12): 1281–1288. doi:10.1016/j.oraloncology.2012.05.024.

Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer

Missak Haigentz Jr.^{a,b}, Mimi Kim^c, Catherine Sarta^b, Juan Lin^c, Roger S. Keresztes^d, Bruce Culliney^e, Anu G. Gaba^a, Richard V. Smith^b, Geoffrey I. Shapiro^f, Lucian R. Chiriac^g, John M. Mariadason^a, Thomas J. Belbin^h, John M. Greallyⁱ, John J. Wright^j, and Robert I. Haddad^f

^aDivision of Oncology, Department of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

^bDepartment of Otorhinolaryngology-Head and Neck Surgery, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

^cDivision of Biostatistics, Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, NY

^dDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY

^eDivision of Oncology, Department of Medicine, Beth Israel Medical Center, New York, NY

^fDepartment of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

^gDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

^hDepartment of Pathology, Albert Einstein College of Medicine, Bronx, NY

ⁱDepartment of Genetics, Albert Einstein College of Medicine, Bronx, NY

^jInvestigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, MD

Abstract

Objectives—Patients with advanced squamous cell carcinoma of the head and neck (SCCHN) have limited treatment options. Inhibition of histone deacetylases (HDACs) represents a novel therapeutic approach warranting additional investigation in solid tumors.

Methods—A phase II trial of single agent romidepsin, an HDAC inhibitor, was performed in 14 patients with SCCHN who provided consent for pre- and post-therapy samples of accessible tumor, blood and uninvolved oral mucosa. Romidepsin was administered at 13 mg/m² as a 4-hour

© 2012 Elsevier Ltd. All rights reserved.

Corresponding Author: Missak Haigentz, Jr., MD, Associate Professor of Clinical Medicine and Clinical Otorhinolaryngology-Head and Neck Surgery, Albert Einstein College of Medicine/Montefiore Medical Center, 111 East 210th Street, Hofheimer Room 100, Bronx, NY 10467, Tel. 718-920-4826, Fax 718-798-7474, mhaigent@montefiore.org.

Conflict of interest statement: None declared.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

intravenous infusion on days 1, 8 and 15 of 28 day cycles, with response assessment by RECIST every 8 weeks.

Results—Objective responses were not observed, although 2 heavily pretreated patients had brief clinical disease stabilization. Observed toxicities were expected, including frequent severe fatigue. Immunohistochemical analysis of 7 pre- and post-treatment tumor pairs demonstrated induction of p21^{Waf1/Cip1} characteristic of HDAC inhibition, as well as decreased Ki67 staining. Exploratory microarray analyses of mucosal and tumor samples detected changes in gene expression following romidepsin treatment that were most commonly associated with regulation of transcription, cell cycle control, signal transduction, and electron transport. Treatment with romidepsin did not alter the extent of DNA methylation of candidate gene loci (including *CDHI* and *hMLH1*) in SCCHN tumors.

Conclusions—Single agent romidepsin has limited activity for the treatment of SCCHN but can effectively achieve tumor-associated HDAC inhibition. Although tolerability of romidepsin in this setting may be limiting, further evaluation of other HDAC inhibitors in combination with active therapies may be justified.

Keywords

romidepsin; head and neck cancer; squamous cell carcinoma; histone deacetylase (HDAC) inhibitors; phase II trial

Introduction

Of the 40,000 new cases of squamous cell carcinoma of the head and neck (SCCHN) diagnosed in the United States annually, approximately 30% of patients will ultimately have either unresectable locally recurrent or metastatic disease¹. Most combination cytotoxic chemotherapy regimens, though improving response rates as compared to single agents in randomized trials, have historically failed to increase overall survival beyond 6–8 months^{2–6}. Although cetuximab is active as a single agent⁷ and improves survival in combination with platinum-based chemotherapy⁸, very limited options exist for patients experiencing disease progression, and new therapeutic approaches are clearly needed.

Romidepsin (FK 228, FR 901228, depsipeptide), a unique bicyclic peptide originally isolated from *Chromobacterium violaceum* strain 968, is a potent inhibitor of the enzyme histone deacetylase (HDAC). Deregulated acetylation of histones is thought to play an important role in the pathogenesis of hematological as well as solid tumors by changing the chromatin structure and transcription of genes involved in cell cycle control, differentiation and apoptosis. Overexpression of HDAC proteins (HDAC 2 and HDAC 6) has been observed in oral SCCHN tumors, correlating with advanced tumor stage^{9,10} and poor patient survival¹⁰. Romidepsin has recently received FDA approval indications in cutaneous and peripheral T-cell lymphoma and has shown preclinical activity and potent radiosensitization properties in a broad range of solid tumors, including SCCHN^{11–13}.

We conducted an NCI/CTEP-sponsored phase II trial of romidepsin in SCCHN patients to assess the anticancer activity of this agent in a solid tumor and to critically evaluate its in vivo mechanisms of action and effects on both tumor and normal adjacent tissues.

Patients and methods

Patient selection and eligibility

This single arm phase II study was initiated at Montefiore Medical Center, Weill Cornell Medical College, Beth Israel Medical Center (NY) and the Dana-Farber Cancer Institute and

was conducted through the New York Cancer Consortium (trial registration number NCT 00084682). The institutional review board of each institution approved the trial, and from June 2005–October 2008, 14 patients provided informed consent and were enrolled.

Eligible patients had squamous cell carcinoma of the head and neck, excluding nasopharyngeal carcinoma, that was recurrent or metastatic and incurable with surgery or radiation therapy. Patients could have received any number of prior chemotherapy regimens for unresectable, recurrent or metastatic disease that must have been completed at least 4 weeks prior to study entry. Additional criteria included age ≥ 18 years, normal organ and marrow function and Eastern Cooperative Oncology Group performance status of 0 to 2. Due to concerns regarding potential for romidepsin-induced cardiotoxicity, patients were excluded if they had prior history of arrhythmias, cardiac hypertrophy, myocardial infarction or congestive heart failure.

Treatment plan

Romidepsin was administered at a dose of 13 mg/m² as a 4-hour intravenous infusion on days 1, 8, and 15 of each 28-day cycle. As romidepsin is moderately emetogenic, prophylactic antiemetics were administered. Patients were assessed with radiographic disease measurements at two cycle (8 week) intervals. Toxicities were graded using National Cancer Institute CTCAE v.3.0.

Statistical considerations

The primary objective of this phase II trial was to determine clinical efficacy of romidepsin in patients with SCCHN. For this objective, the primary endpoint was disease control (i.e., achievement of complete response, partial response, or stable disease) at 8 weeks using RECIST. Simon's optimal two-stage design was used, providing early termination of the trial given a sufficiently inactive regimen. The target disease control rate (defined as CR + PR + SD, without evidence of clinical deterioration) at 8 weeks was assumed to be 60%, and a rate less than 40% was considered to be clinically unimportant. Based on these assumptions, first stage accrual of 18 patients was planned, with an additional 28 patients if 8 or more patients achieved response or stable disease. The power of the study was 0.90.

Samples

Peripheral blood samples (10 mL) were collected before and after the initial 4-hour romidepsin administration (Cycle #1, day #1 only) using a blue-speckled top Vacutainer CPT cell separation tube containing sodium citrate gel and density gradient media, and peripheral blood mononuclear cells (PBMCs) were subsequently collected by centrifugation.

Pre- and post-treatment oral mucosa specimens for RNA isolation were obtained from patients using the OralCDx system (CDx Laboratories, Suffern, NY) on day 1 of the first cycle of therapy. The brush samples were taken from separate mucosal surfaces not involved with obvious cancer or mucositis.

Tumor biopsies were obtained from primary lesions or from an involved metastatic site. The baseline biopsy was obtained within 4 weeks prior to starting romidepsin, and all efforts were made to take the post-treatment biopsy from the same anatomic site within 24 hours following the administration of the third (day 15) dose of romidepsin on the first cycle. A fresh portion of each tumor biopsy was immediately flash-frozen in liquid nitrogen and stored at -80°C for further analysis. Tumor samples were also fixed in formalin and embedded in paraffin for immunohistochemical analysis, and all were histologically confirmed for presence of SCCHN.

Histone acetylation in PBMCs

Histone proteins were isolated from PBMCs by acid extraction and histone H3 acetylation was assessed by western blot analysis with a rabbit-anti-acetylated histone H3 antibody (Upstate Bioscientific, Lake Placid, NY), as previously described^{14,15}.

Tumor immunohistochemistry

Immunohistochemical analysis for p21^{Waf1/Cip1} (Signal Transduction, Lexington, KY) and Ki67 was performed on formalin-fixed, paraffin embedded 5µm tumor samples. The immunostained slides were examined by light microscopy by a pathologist (LRC) who had no information about the treatment status or outcome of patients. Ki-67 and p21 were recorded as the number of Ki-67 or p21-positive tumor cells per 1000 tumor cells counted in five high-power fields (1 mm², Olympus BX41 microscope, 400x magnification). In cases with considerable intratumoral heterogeneity and irregular distribution of Ki-67 and p21 positive tumor cells, we selected for evaluation the fields with the greatest number of tumor cells staining for these markers (hot spots). For each patient, we recorded both Ki-67 and p21 as average values per 200 cells. The staining intensity was recorded according to the manufacturer recommendations as: 0, if tumor cells had complete absence of staining; 1+, if tumor cells had faint, barely perceptible staining or weak heterogeneous staining; 2+, if tumor cells had strong staining. Tumors with 1+ and 2+, expression were interpreted as positive for Ki-67 or p21 expression, and tumors with no expression (0 score) were interpreted as negative.

cDNA microarray analyses

In order to rule out gene expression alterations due to stromal cell contamination, each tumor specimen used in our studies contained greater than 70% cancer cells by analysis of corresponding hematoxylin and eosin stained sections. Following RNA extraction, linear amplification of tissue mRNA and subsequent fluorescent labeling of corresponding cDNA was carried out using the MessageAmp T7 linear amplification kit (Ambion, Austin, TX) and cDNA labeling protocols developed at the Albert Einstein College of Medicine. Hybridization to 19,297 gene cDNA microarrays was carried out overnight at 50°C in a buffer containing 30% formamide, 3X SSC, 0.75% SDS and 100 ng of human Cot-1 DNA. Slides were scanned using the GenePix 4000A microarray scanner. Red (Cy5) and green (Cy3) signal intensities for each element on the array were calculated using the GenePix Pro 3.0 software package.

After the microarray data was filtered based on signal to noise ratio and lowess-normalized, pretreatment levels were compared to post-romidepsin treatment expression levels by computing the empirical Bayes moderated t-statistic, and the Benjamini-Hochberg method was applied to correct for multiple testing. Significant genes were identified by P-value 0.05 and fold-difference in mean expression ≥ 2 .

DNA methylation analyses

We applied the technique of bisulfite sequencing¹⁶ to study tumor DNA methylation status of *CDH1* (encoding for E-cadherin) and *hMLH1* (encoding a DNA mismatch repair protein), frequently hypermethylated loci in SCCHN tumors^{17,18}, as well as *H19* and *SNRPN*, normally imprinted loci, pre- and post-romidepsin treatment.

Results

Patient characteristics

Fourteen patients were enrolled in the study and received treatment, 13 of whom were evaluable for response. One patient withdrew consent after the first dose of romidepsin due to toxicity and was not evaluable for response evaluation. All patients were evaluable for toxicity.

Patient demographics and characteristics are presented in Table 1. The patient population was heavily pretreated. All patients had prior chemoradiotherapy as part of curative-intent therapy, 5 patients had prior re-irradiation to the head and neck, and 1 patient had prior palliative radiotherapy to the sole site of measurable disease (chest). Although the median of prior systemic palliative therapies was 1 (range 0–4), 5 patients (36%) had at least 2 prior systemic therapies for recurrent or metastatic disease.

Safety and tolerability

A total of 68 doses of romidepsin were administered to the 14 patients enrolled in this study. Adverse events at least possibly related to romidepsin (worst grade seen, at any timepoint) are presented in Table 2. Common toxicities associated with romidepsin were nausea, vomiting, constipation, and fatigue. Although most adverse events were moderate and were grade 1 or 2 in severity, grade 3 or 4 fatigue developed in 5 patients (36%) and was clinically associated with disease progression. Hematological toxicities were generally mild, including thrombocytopenia (2 patients, one with grade 4 toxicity) and exacerbation of pre-existing anemia; leukopenia was not observed. Aside from grade 3 hypotension in 1 patient and grade 4 thrombosis (pulmonary embolism) in 1 patient, no clinically significant cardiovascular toxicity was observed.

Tumor responses

Thirteen patients were evaluable for response to romidepsin. Although no partial responses were observed, 2 patients had a best response of stable disease, resulting in a disease control rate of 15.4% (95% CI: 1.9% – 45.5%). However, 9 patients experienced disease progression, including 2 patients with progressive disease after one cycle of therapy. Symptomatic deterioration was noted in 2 other patients, following 1 and 2 cycles of therapy, which was counted as evidence of lack of clinical benefit; although measurable disease was stable according to RECIST, clinical deterioration was associated with rapid demise. As the first stage goal of 8 patients with disease control was not achievable, patient accrual to the protocol was terminated early at 14 patients for lack of efficacy.

Three heavily pretreated patients had best objective response of stable disease after 2 cycles of therapy, though one was associated with symptomatic deterioration. One of these patients (patient #6, laryngeal cancer) had clear disease progression to palliative chemotherapy (docetaxel) prior to enrollment. The patient was removed from the trial for clinical deterioration after 4 cycles of therapy. Another patient with disease stabilization (patient #3, base of tongue cancer, Fig. 1A) had experienced frank disease progression to four prior palliative chemotherapy regimens prior to enrollment, including cytotoxic chemotherapy (docetaxel, methotrexate), gefitinib, and a phase I trial of an investigational agent. This patient experienced disease progression on romidepsin after 4 cycles of therapy. Patient #10, a patient with recurrent supraglottic laryngeal cancer with prior disease progression after palliative combination of docetaxel, carboplatin and cetuximab, experienced symptomatic deterioration immediately after 2 cycles of romidepsin, necessitating removal from the study and referral to hospice care.

Analysis of PBMCs for histone hyperacetylation

Six patients had sufficient yield of PBMCs for pre- and post-therapy comparisons. Immediately following the initial 4 hour infusion of romidepsin, variable histone H3 hyperacetylation, with increase ranging from 10% to 490%, was observed in all tested samples (Fig. 1B) but did not correlate with response assessments. As a control, ex vivo exposure of PBMCs from a non-cancer volunteer (MH) to micromolar concentrations of romidepsin demonstrated histone H3 hyperacetylation at 4 hours (Fig. 1C).

Tumor immunohistochemistry

Seven pairs of pre-therapy and cycle 1, day 16 tumor biopsies were available for immunohistochemical analysis of p21^{Waf1/Cip1} and Ki67 expression. Increased p21^{Waf1/Cip1} staining post-romidepsin treatment was observed in all tested tumors (Fig. 2A), and in parallel, all post-treatment samples had reduced or stable levels of Ki67 staining (Fig. 2B).

cDNA microarray analyses

Post-amplification RNA yields from four pairs of pre-therapy and post-treatment (cycle 1, day 16) tumor biopsies and four pairs of pre- and post-treatment (cycle 1, day 1) oral mucosal samples were sufficient for hybridization to 19,297 element cDNA microarrays for gene expression analysis. Of 641 differentially expressed genes identified in the SCCHN tumors, 253 genes were significantly up-regulated, while 388 genes were significantly down-regulated. In mucosal specimens, 151 genes were significantly up-regulated, while 368 genes were significantly down-regulated (Supplemental Table 1).

DNA methylation studies

Analysis of extent of DNA methylation in individual CpG dinucleotide positions in the *CDH1* and *hMLH1* tumor suppressor genes and the normally imprinted *H19* and *SNRPN* loci was conducted from pre- and post-therapy (cycle 1, day 16) DNA obtained from 7 tumor specimens (Fig. 3). Interpatient variability in baseline DNA methylation was noted at each CpG site tested for both tumor suppressor and normally imprinted loci, although the extent of DNA methylation for the tumor suppressor promoter loci was lower at baseline than for the imprinted *H19* and *SNRPN* loci, as expected (data not shown). No consistent change in DNA methylation extent was observed for the evaluated loci post-romidepsin therapy.

Discussion

Although disease stabilization was observed in a few heavily pretreated patients, the efficacy of romidepsin in this study was inadequate to justify its further clinical development in SCCHN as a single agent. This outcome appears to be a consistent clinical observation of romidepsin and other HDAC inhibitors as single agents in SCCHN and other solid tumors^{19–26}.

Nevertheless, HDAC inhibitors have been successfully combined with cytotoxic chemotherapy and biological agents with evidence of enhanced anticancer activity. Romidepsin synergistically enhances the sensitivity of non-small cell lung cancer cells to erlotinib²⁷ and increases cytotoxicity of docetaxel in preclinical models of androgen-independent prostate cancer²⁸. Ramalingam et al.²⁹ recently published results of a randomized phase II trial of vorinostat, a class I and II HDAC inhibitor, or placebo in combination with paclitaxel and carboplatin for patients with advanced non-small cell lung cancer in which treatment with vorinostat was associated with significantly improved response rate and a trend toward improved median progression-free and overall survival. HDAC inhibitors have additionally demonstrated preclinical evidence of

radiosensitization³⁰, and several ongoing clinical trials are testing this hypothesis. While single agent activity is poor, additional, hypothesis-driven investigation may be warranted to establish a role for romidepsin and other HDAC inhibitors in SCCHN and other solid tumors.

The FDA recently approved romidepsin at a similar dose (14 mg/m²) and same schedule for patients with cutaneous or peripheral T-cell lymphoma who have received at least one prior therapy, and romidepsin is associated with frequent and durable objective tumor response in these settings^{31–33}. Treatment is associated with frequent gastrointestinal toxicities, anorexia, and fatigue, with grade 3 or 4 fatigue occurring in up to 19% of patients³⁴. In our study, the frequency of observed grade 3 or 4 fatigue was notably high, occurring in 36% of patients, but was always associated with disease progression.

Romidepsin is a potent inhibitor of HDAC activity. In a phase II trial in patients with cutaneous T-cell lymphoma, extent of histone H3 hyperacetylation in PBMCs at 24 hours following romidepsin treatment was significantly associated with clinical response³⁵. Although we observed increased histone H3 acetylation in normal PMBCs of several SCCHN patients post-initial romidepsin infusion (Fig. 1B), it did not correlate with clinical response assessments.

One of the most commonly induced genes by HDAC inhibitors is the cdk inhibitor p21^{Waf1/Cip1}³⁶. Induction of p21^{Waf1/Cip1} occurs in a p53-independent fashion and contributes to the cell cycle arrest and differentiation induced by members of this drug class. In all tested SCCHN tumors, p21^{Waf1/Cip1} protein expression was up-regulated and correlated with a decrease in tumor cell proliferation as evaluated by Ki67 expression. The high frequency of Ki67 decline and reduced proliferation in tumors post-romidepsin suggests more disease stabilization than was clinically observed. However, post-therapy biopsies were obtained on day 16 of cycle 1, whereas tumor response assessment was 4–6 weeks later, suggesting the possibility of rapid development of tumor resistance following the first cycle of therapy. Romidepsin is a known P-glycoprotein substrate, and resistance to romidepsin may be related to reversible induction of histone acetylation and chromatin changes leading to enhanced *MDR-1* transcription³⁷.

As an HDAC inhibitor, romidepsin is thought to act primarily by altering transcriptional activity. Although our exploratory cDNA expression microarray data indicate both up-regulated and down-regulated genes with at least a 2-fold change in normal mucosa and SCCHN tumors following romidepsin exposure, the tumor and mucosal samples demonstrate a preponderance of down-regulated genes (Supplemental Table 1). The observed gene expression changes in tumor and mucosal cells represent a broad range of biological processes, including transcriptional regulation, cell cycle control, signal transduction and electron transport. Tumor genes noted to be up-regulated following romidepsin exposure included *IGFBP3*, a gene involved in negative regulation of cell growth that is characteristically up-regulated following HDAC inhibition³⁸. Down-regulated tumor cell cycle genes include *E2F2* and cyclin B1 (*CCNB1*), a known HDAC-regulated gene³⁹. Interestingly, the expression of *HDAC6*, associated with tumor aggressiveness in SCCHN⁹, and *EGFR* was down-regulated in SCCHN tumors following romidepsin, the mechanism and clinical significance of which warrants further study. Of note, recent preclinical studies of the HDAC inhibitor valproic acid in combination with hydroxyurea have shown downregulation of EGFR protein expression and triggering of apoptosis in SCCHN cells and xenografts⁴⁰.

Although increased p21 protein expression was observed in all post-treatment tumor specimens, no significant change in p21 mRNA expression was observed in the microarray

studies. As our post-treatment biopsies were obtained at 24 hours following romidepsin administration, p21 transcription may have returned to baseline, while p21 protein, which is longer lasting, was still up-regulated. This hypothesis is supported by known *in vivo* effects of romidepsin on p21 promoter region histone acetylation by chromatin immunoprecipitation studies in chronic lymphocytic leukemia; a maximal increase in p21 protein expression and promoter acetylation was observed at 4 hours following romidepsin administration, while acetylation returned to baseline at 24 hours ⁴¹.

The gene expression changes in mucosal samples, sampled immediately prior and at two hours following the initial romidepsin infusion (cycle 1, day 1), may reflect early effects of HDAC inhibition. Up-regulated genes in the mucosal specimens include annexin A1 (*ANXA1*), a cell cycle regulatory gene known to be induced by romidepsin ⁴². Of note, the *MYCN* oncogene was found to be up-regulated in mucosal specimens. Interestingly, the tumor suppressor *DAPK1* was also found to be down-regulated. The observation of romidepsin-induced changes in gene expression in normal mucosal specimens reflect changes in the mucosal location of head and neck carcinogenesis, some of which may predispose to oncogenesis; this observation may have implications for studies of HDAC inhibitors in SCCHN prevention.

Although HDAC inhibitors as single agents have not been known to reverse the hypermethylated state of tumor suppressor genes in tumor cell lines, they may have indirect effects on DNA methylation and other epigenetic processes. Of note, activator-protein 2- α (AP-2 α), overexpressed in approximately 70% of SCCHN tumors, has recently been demonstrated to target methylation of *hMLH1* in SCCHN cells via HDAC recruitment, resulting in microsatellite instability; treatment with trichostatin A, an inhibitor of class I and II HDACs, results in decreased *hMLH1* methylation ⁴³. It is known that HDAC inhibitors including romidepsin synergistically increase the activity of hypomethylating agents ⁴⁴, and several clinical trials of romidepsin and decitabine have been initiated. We studied four loci, including 2 tumor suppressor genes (*CDH1* and *hMLH1*) and 2 imprinted genes (*H19* and *SNRPN*), each with a CpG island at its transcription start site, using pyrosequencing as a *quantitative* measure of methylation pre- and post-romidepsin therapy. Our preliminary analysis indicates that romidepsin does not alter the extent of tumor DNA methylation for any of the evaluated genes.

This study illustrates that the model of SCCHN, associated with frequent anatomical accessibility, can be used for extensive translational research in solid tumors. Although the clinical efficacy of romidepsin as a single agent in incurable SCCHN is limited, our observations provide evidence of HDAC inhibitor-induced mechanistic activity in solid tumors that may justify further study of HDAC inhibitors in combination with existing active therapies.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This study was supported by the American Society of Clinical Oncology Career Development Award and NIH grant R21-CA110342 (M.H.), U01-CA062490, and N01-CM-62204. We thank the participating patients and their families for their involvement in this study. We thank Leslie Adrien of the Department of Pathology at the Albert Einstein College of Medicine for expert technical assistance with cDNA microarray and methylation analyses as well as Donna Skinner, Treeve Currie and Sabina Signoretti of the Dana-Farber/Harvard Cancer Center Pathology Core for assistance with slide preparation and immunohistochemistry. We also thank Dr. Nicolas F. Schlecht for the use of fixative for mucosal samples, Dr. Kevin Ferrick for reviewing patient ECGs, and Dr. Marshall R. Posner and Dr. Joseph A. Sparano for valuable discussions.

References

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. *CA Cancer J Clin.* 2011; 61(4): 212–236. [PubMed: 21685461]
2. Hong WK, Schaefer S, Issell B, Cummings C, Luedke D, Bromer R, et al. A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck. *Cancer.* 1983; 52(2):206–210. [PubMed: 6190545]
3. Eisenberger M, Krasnow S, Ellenberg S, Silva H, Abrams J, Sinibaldi V, et al. A comparison of carboplatin plus methotrexate versus methotrexate alone in patients with recurrent and metastatic head and neck cancer. *J Clin Oncol.* 1989; 7(9):1341–1345. [PubMed: 2671289]
4. Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS, Knight W, Hochster H, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. *J Clin Oncol.* 1992; 10(2):257–263. [PubMed: 1732427]
5. Murphy BLY, Cella D, Karnad A, Hussain M, Forastiere A. Phase III study comparing cisplatin (C) and 5-fluorouracil (F) versus cisplatin and paclitaxel (P) in metastatic/recurrent head and neck cancer (MHNC). *Proceed Am Soc Clin Oncol.* 2001; 20:894a.
6. Samlowski WE, Moon J, Kuebler JP, Nichols CR, Gandara DR, Ozer H, et al. Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study. *Cancer Invest.* 2007; 25(3):182–188. [PubMed: 17530488]
7. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. *J Clin Oncol.* 2007; 25(16):2171–2177. [PubMed: 17538161]
8. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. *N Engl J Med.* 2008; 359(11):1116–1127. [PubMed: 18784101]
9. Sakuma T, Uzawa K, Onda T, Shiiba M, Yokoe H, Shibahara T, et al. Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. *Int J Oncol.* 2006; 29(1):117–124. [PubMed: 16773191]
10. Chang HH, Chiang CP, Hung HC, Lin CY, Deng YT, Kuo MY. Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients. *Oral Oncol.* 2009; 45(7):610–614. [PubMed: 18951835]
11. Ueda H, Manda T, Matsumoto S, Mukumoto S, Nishigaki F, Kawamura I, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by *Chromobacterium violaceum* No. 968. III. Antitumor activities on experimental tumors in mice. *J Antibiot (Tokyo).* 1994; 47(3):315–323. [PubMed: 8175484]
12. Rajgolikar G, Chan KK, Wang HC. Effects of a novel antitumor depsipeptide, FR901228, on human breast cancer cells. *Breast Cancer Res Treat.* 1998; 51(1):29–38. [PubMed: 9877027]
13. Zhang Y, Jung M, Dritschilo A. Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. *Radiat Res.* 2004; 161(6):667–674. [PubMed: 15161353]
14. Mariadason JM, Corner GA, Augenlicht LH. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. *Cancer Res.* 2000; 60(16):4561–4572. [PubMed: 10969808]
15. Mariadason JM, Velcich A, Wilson AJ, Augenlicht LH, Gibson PR. Resistance to butyrate-induced cell differentiation and apoptosis during spontaneous Caco-2 cell differentiation. *Gastroenterology.* 2001; 120(4):889–899. [PubMed: 11231943]
16. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. *Proc Natl Acad Sci U S A.* 1996; 93(18):9821–9826. [PubMed: 8790415]

17. Marsit CJ, Posner MR, McClean MD, Kelsey KT. Hypermethylation of E-cadherin is an independent predictor of improved survival in head and neck squamous cell carcinoma. *Cancer*. 2008; 113(7):1566–1571. [PubMed: 18711702]
18. Liu K, Huang H, Mukunyadzi P, Suen JY, Hanna E, Fan CY. Promoter hypermethylation: an important epigenetic mechanism for hMLH1 gene inactivation in head and neck squamous cell carcinoma. *Otolaryngol Head Neck Surg*. 2002; 126(5):548–553. [PubMed: 12075230]
19. Whitehead RP, Rankin C, Hoff PM, Gold PJ, Billingsley KG, Chapman RA, et al. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). *Invest New Drugs*. 2009; 27(5):469–475. [PubMed: 18941712]
20. Molife LR, Attard G, Fong PC, Karavasilis V, Reid AH, Patterson S, et al. Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). *Ann Oncol*. 2009
21. Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li X, Kunst TF, et al. Clinical and molecular responses in lung cancer patients receiving Romidepsin. *Clin Cancer Res*. 2008; 14(1):188–198. [PubMed: 18172270]
22. Stadler WM, Margolin K, Ferber S, McCulloch W, Thompson JA. A phase II study of depsipeptide in refractory metastatic renal cell cancer. *Clin Genitourin Cancer*. 2006; 5(1):57–60. [PubMed: 16859580]
23. Blumenschein GR Jr, Kies MS, Papadimitrakopoulou VA, Lu C, Kumar AJ, Ricker JL, et al. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. *Invest New Drugs*. 2008; 26(1):81–87. [PubMed: 17960324]
24. Modesitt SC, Sill M, Hoffman JS, Bender DP. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol*. 2008; 109(2):182–186. [PubMed: 18295319]
25. Traynor AM, Dubey S, Eickhoff JC, Kolesar JM, Schell K, Huie MS, et al. Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study. *J Thorac Oncol*. 2009; 4(4):522–526. [PubMed: 19347984]
26. Luu TH, Morgan RJ, Leong L, Lim D, McNamara M, Portnow J, et al. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. *Clin Cancer Res*. 2008; 14(21):7138–7142. [PubMed: 18981013]
27. Zhang W, Peyton M, Xie Y, Soh J, Minna JD, Gazdar AF, et al. Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines. *J Thorac Oncol*. 2009; 4(2):161–166. [PubMed: 19179890]
28. Zhang Z, Stanfield J, Frenkel E, Kabbani W, Hsieh JT. Enhanced therapeutic effect on androgen-independent prostate cancer by depsipeptide (FK228), a histone deacetylase inhibitor, in combination with docetaxel. *Urology*. 2007; 70(2):396–401. [PubMed: 17826527]
29. Ramalingam SS, Maitland ML, Frankel P, Argiris AE, Koczywas M, Gitlitz B, et al. Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non-Small-Cell Lung Cancer. *J Clin Oncol*. 2009
30. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. *J Clin Oncol*. 2009; 27(32):5459–5468. [PubMed: 19826124]
31. Piekarczyk RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. *J Clin Oncol*. 2009; 27(32):5410–5417. [PubMed: 19826128]
32. Piekarczyk RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. *Blood*. 2011; 117(22):5827–5834. [PubMed: 21355097]
33. Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy. *J Clin Oncol*. 2012; 30(6):631–636. [PubMed: 22271479]
34. Celgene Corporation. Prescribing Information, Romidepsin (ISTODAX). 2011.

35. Bates SE, Zhan Z, Steadman K, Obrzut T, Luchenko V, Frye R, et al. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. *Br J Haematol*. 2009
36. Richon VM, O'Brien JP. Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment. *Clin Cancer Res*. 2002; 8(3):662–664. [PubMed: 11895892]
37. Xiao JJ, Huang Y, Dai Z, Sadee W, Chen J, Liu S, et al. Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithi a-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines. *J Pharmacol Exp Ther*. 2005; 314(1):467–475. [PubMed: 15833893]
38. Choi HS, Lee JH, Park JG, Lee YI. Trichostatin A, a histone deacetylase inhibitor, activates the IGFBP-3 promoter by upregulating Sp1 activity in hepatoma cells: alteration of the Sp1/Sp3/HDAC1 multiprotein complex. *Biochem Biophys Res Commun*. 2002; 296(4):1005–1012. [PubMed: 12200149]
39. Archer SY, Johnson J, Kim HJ, Ma Q, Mou H, Daesety V, et al. The histone deacetylase inhibitor butyrate downregulates cyclin B1 gene expression via a p21/WAF-1-dependent mechanism in human colon cancer cells. *Am J Physiol Gastrointest Liver Physiol*. 2005; 289(4):G696–703. [PubMed: 16160080]
40. Stauber RH, Knauer SK, Habtemichael N, Bier C, Unruhe B, Weisheit S, et al. A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer. *Oncotarget*. 2012; 3(1):31–43. [PubMed: 22289787]
41. Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M, et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. *Blood*. 2005; 105(3):959–967. [PubMed: 15466934]
42. Tabe Y, Jin L, Contractor R, Gold D, Ruvolo P, Radke S, et al. Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1. *Cell Death Differ*. 2007; 14(8):1443–1456. [PubMed: 17464329]
43. Bennett KL, Romigh T, Eng C. AP-2alpha induces epigenetic silencing of tumor suppressive genes and microsatellite instability in head and neck squamous cell carcinoma. *PLoS One*. 2009; 4(9):e6931. [PubMed: 19742317]
44. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? *Cancer Cell*. 2003; 4(1):13–18. [PubMed: 12892709]

Fig. 1.
A. Stable large lung metastases (arrow) following the initial 2 cycles of romidepsin in a patient (patient #3) with prior chemoradiotherapy and disease progression on four palliative lines of systemic therapy. The pleural effusion seen prior to therapy (dotted arrow) had resolved. B. Results of densitometric analysis indicating modest increase in PMBC histone H3 acetylation following romidepsin administration, and individual responses to therapy. C. Representative western blot of PBMC histone proteins obtained pre-treatment and immediately after the first 4-hour romidepsin infusion, demonstrating histone H3 hyperacetylation (arrow). Positive controls include ex vivo exposure of PBMCs from a non-cancer volunteer (MH) to the HDAC inhibitors trichostatin A (TSA) and romidepsin (Romi). Histone H1 is used as a loading control.

Fig. 2.

Formalin-fixed, paraffin embedded pre- and post-treatment tumor biopsy pairs were stained with anti-p21^{Waf1/Cip1} (A) or Ki67 (B). Tumor cells were scored as 0, 1+ or 2+. The percent positively staining cells is plotted on the y-axis.

Fig. 3. Extent of methylation of individual CpG positions in promoter elements of *CDH1* and *hMLH1* in baseline and post-romidepsin treated SCCHN tumors as determined by bisulfite PCR followed by pyrosequencing.

Table 1**Patient characteristics**

No. patients	14
Gender	
M	11
F	3
Age	
Median	59
Range	46–75
Race/Ethnicity	
Black	1
Caucasian/Hispanic	6
Caucasian/Non-Hispanic	7
ECOG PS	
0	2
1	8
2	4
Primary tumor site	
Oral cavity	2
Oropharynx	6
Hypopharynx	2
Larynx	4
Recurrence status	
Locoregional	9
Metastatic	5
Prior RT	
chemoradiotherapy	14
re-irradiation	5
Palliative	1
Prior palliative systemic therapies	
0	2
1	7
2	3
3	1
4	1

Table 2

Incidence of romidepsin-related adverse events during therapy (N = 14 patients).

Adverse event	Worst Grade (%)			
	1	2	3	4
Blood/bone marrow				
Anemia	2 (14)	0	2 (14)	0
Leukopenia	0	0	0	0
Thrombocytopenia	1 (7)	2 (14)	1 (7)	1 (7)
Cardiac				
Hypertension	1 (7)	0	0	0
Hypotension	0	0	1 (7)	0
Constitutional symptoms				
Fatigue	4 (28)	2 (14)	4 (28)	1 (7)
Gastrointestinal				
Anorexia	0	0	2 (14)	0
Constipation	5 (36)	1 (7)	0	0
Diarrhea	2 (14)	0	0	0
Dyspepsia	1 (7)	0	0	0
Nausea	5 (36)	5 (36)	1 (7)	0
Vomiting	5 (36)	3 (21)	2 (14)	0
Infection				
Lung	0	0	3 (21)	0
Soft tissue	0	0	1 (7)	0
Pain	1 (7)	0	0	0
Vascular				
Thrombosis	0	0	0	1 (7)